Table 3.

Risk of any and osteoporotic fracture among incident MG patients by drug exposure

	Risk of any fracture		Risk of fracture at osteoporotic sites
	Number of fractures	Fully adjusted HR (95 % CI)a	Number of fractures	Fully adjusted HR (95 % CI)a
MG by use of oral glucocorticoids by cumulative dose in grams prednisolone equivalents in the previous year
No oral glucocorticoid use	47	1.00	27	1.00
Any oral glucocorticoid use	28	0.88 (0.52–1.47)	16	0.75 (0.38–1.50)
<2.5 g prednisolone eq	13	0.80 (0.42–1.53)	7	0.63 (0.26–1.53)
2.5–5.0 g prednisolone eq	10	1.11 (0.54–2.26)	5	0.83 (0.31–2.25)
> = 5.0 g prednisolone eq	5	0.73 (0.27–1.94)	4	0.99 (0.31–3.14)
MG by history of drug use in previous 6 months
No oral glucocorticoid use	48	1.00	28	1.00
Oral glucocorticoid use	27	0.97 (0.58–1.63)	15	0.81 (0.40–1.61)
<7.5 mg prednisolone eq/day	10	0.99 (0.49–2.03)	5	0.70 (0.26–1.92)
7.5–15 mg prednisolone eq/day	8	1.00 (0.46–2.16)	3	0.57 (0.17–1.93)
> = 15 mg prednisolone eq/day	9	0.93 (0.44–1.99)	7	1.17 (0.47–2.89)
No antidepressant use	59	1.00	31	1.00
Antidepressant use	16	2.15 (1.22–3.79)	12	3.27 (1.63–6.55)
<20 mg fluoxetine eq/day	9	1.88 (0.92–3.86)	7	2.77 (1.18–6.50)
> = 20 mg fluoxetine eq/day	7	2.61 (1.18–5.80)	5	4.32 (1.64–11.38)
No anxiolytic use	61	1.00	32	1.00
Anxiolytic use	14	1.80 (0.97–3.34)	11	2.18 (1.04–4.57)
<10 mg diazepam eq/day	10	1.72 (0.85–3.47)	8	2.10 (0.90–4.86)
> = 10 mg diazepam eq/day	4	2.07 (0.73–5.82)	3	2.41 (0.71–8.12)
No anticonvulsant use	64	1.00	36	1.00
Anticonvulsant use	11	5.36 (2.76–10.39)	7	6.88 (2.91–16.27)
<1.0 g carbamazepine eq/day	8	4.88 (2.27–10.50)	5	5.45 (2.03–14.62)
> = 1.0 g carbamazepine eq/day	3	7.10 (2.13–23.62)	2	18.18 (3.88–85.15)
No antipsychotic use	74	1.00	42	1.00
Antipsychotic use	1	1.30 (0.17–9.76)	1	1.41 (0.17–11.65)

eq equivalents

^aAdjusted for the same confounders as described below Table 2 for any and osteoporotic fracture, but the confounder is not added to the model if it is similar to the drug being investigated